Bruce D. Minsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bruce D. Minsky has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
- Ethan Bernard Ludmir
Department of Gastrointestinal Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
67 shared publications - Joseph Abi Jaoude
Department of Radiation Oncology, Stanford University, Stanford, CA
62 shared publications - Ramez Kouzy
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
62 shared publications - Timothy A. Lin
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030
51 shared publications - Alexander D. Sherry
Department of Radiation Oncology, Mayo Clinic, Rochester, MN
50 shared publications - Michael James Overman
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
50 shared publications
Latest Publications
- Open Access
Perioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial
Background/Objectives: Immunotherapy (IO) has demonstrated survival benefits in metastatic gastroesophageal cancers, and current data supports perioperative IO in localized adenocarcinomas. Radiation may further enhance IO response through immunologic priming. This study evaluates the feasibility, safety, and preliminary efficacy of incorporating IO into a chemoradiation-based perioperative strategy for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Methods: This single-arm, phase I/II study enrolled adults with untreated, locally advanced, resectable gastric or GEJ adenocarcinoma between February 2019 and June 2023. The treatment protocol consisted of induction chemotherapy (oxaliplatin + 5-fluorouracil), induction IO (nivolumab + ipilimumab), concurrent immune-chemoradiation (nivolumab, 5-fluorouracil, and 45 Gy IMRT/VMAT), surgical resection, and adjuvant nivolumab for residual disease. Primary endpoints were safety and feasibility; secondary endpoints included the pathologic complete response (pCR), R0 resection rate, disease-free survival (DFS), overall survival (OS), and biomarker analysis. Results: In total, 30 patients were enrolled, and 23 underwent resection. Grade 4 treatment-related toxicities occurred in three patients (10%), including acute kidney injury, myocarditis/myositis/myasthenia gravis overlap syndrome, and neutropenia. Among surgical patients, the pCR rate was 39.1% (95% CI: 19.7–61.5%), and the intention-to-treat pCR rate was 30% (95% CI: 14.7–49.4%). R0 resection was achieved in 87% of cases. Median DFS among resected patients was 40.2 months (95% CI: 21.6–NE). Median OS was 43.7 months (95% CI: 30.7–NE), with 2-, 3-, and 5-year OS rates of 73.3%, 57.5%, and 47.9%, respectively. Conclusions: This multimodality approach incorporating IO with chemotherapy and chemoradiation demonstrated a manageable safety profile and an encouraging pCR rate, supporting further evaluation.
Open AccessPerioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial
Background/Objectives: Immunotherapy (IO) has demonstrated survival benefits in metastatic gastroesophageal cancers, and current data supports perioperative IO in localized adenocarcinomas. Radiation may further enhance IO response through immunologic priming. This study evaluates the feasibility, safety, and preliminary efficacy of incorporating IO into a chemoradiation-based perioperative strategy for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Methods: This single-arm, phase I/II study enrolled adults with untreated, locally advanced, resectable gastric or GEJ adenocarcinoma between February 2019 and June 2023. The treatment protocol consisted of induction chemotherapy (oxaliplatin + 5-fluorouracil), induction IO (nivolumab + ipilimumab), concurrent immune-chemoradiation (nivolumab, 5-fluorouracil, and 45 Gy IMRT/VMAT), surgical resection, and adjuvant nivolumab for residual disease. Primary endpoints were safety and feasibility; secondary endpoints included the pathologic complete response (pCR), R0 resection rate, disease-free survival (DFS), overall survival (OS), and biomarker analysis. Results: In total, 30 patients were enrolled, and 23 underwent resection. Grade 4 treatment-related toxicities occurred in three patients (10%), including acute kidney injury, myocarditis/myositis/myasthenia gravis overlap syndrome, and neutropenia. Among surgical patients, the pCR rate was 39.1% (95% CI: 19.7–61.5%), and the intention-to-treat pCR rate was 30% (95% CI: 14.7–49.4%). R0 resection was achieved in 87% of cases. Median DFS among resected patients was 40.2 months (95% CI: 21.6–NE). Median OS was 43.7 months (95% CI: 30.7–NE), with 2-, 3-, and 5-year OS rates of 73.3%, 57.5%, and 47.9%, respectively. Conclusions: This multimodality approach incorporating IO with chemotherapy and chemoradiation demonstrated a manageable safety profile and an encouraging pCR rate, supporting further evaluation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S4 shows the cause of death for patients treated with chemotherapy only and patients treated with radiation therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S4 shows the cause of death for patients treated with chemotherapy only and patients treated with radiation therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S3 shows the COX regression for overall survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S3 shows the COX regression for overall survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Fig S3 shows the overall survival difference between patients treated with radiation therapy and patients treated with chemotherapy only from the NCDB.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Fig S3 shows the overall survival difference between patients treated with radiation therapy and patients treated with chemotherapy only from the NCDB.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S2 shows the treatment details for patients treated with radiation therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S2 shows the treatment details for patients treated with radiation therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S5 shows the adverse events of patients treated with radiation therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S5 shows the adverse events of patients treated with radiation therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S1 shows the treatment details for the chemotherapy cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S1 shows the treatment details for the chemotherapy cohort.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Fig S1 shows the overall survival difference between patients treated with radiation therapy or chemotherapy only based on M stage.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Fig S1 shows the overall survival difference between patients treated with radiation therapy or chemotherapy only based on M stage.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S6 shows the overall survival COX regression based on mutational status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Table S6 shows the overall survival COX regression based on mutational status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Purpose:Ablative radiotherapy (RT) improves clinical outcomes in patients with unresectable intrahepatic cholangiocarcinoma (ICC). Applicability to “supermassive” ICC remains uncertain given smaller tumor diameters in previous studies. We hypothesize that supermassive ICCs are not mutationally or histopathologically different from nonsupermassive ICCs and so would respond favorably to ablative RT.Experimental Design:This is a retrospective study of patients with supermassive ICC treated at the University of Texas MD Anderson Cancer Center (MDACC) and the National Cancer Database (NCDB). Patients treated at MDACC with unresectable ICC, ≥10 cm in diameter, treated with ablative RT or chemotherapy alone were included. Among NCDB patients, patients treated with chemotherapy alone were included. We analyzed overall survival (OS), tumor-related liver failure (TRLF), and treatment toxicity. We further analyzed mutational status and histopathology in supermassive and nonsupermassive ICC tumors.Results:We identified 63 patients treated at MDACC. Patients treated with RT showed improved OS compared with patients treated with chemotherapy alone (median OS: 28.7 vs. 11.9 months; adjusted HR = 0.4; P = 0.02). Patients treated with chemotherapy alone had a higher rate of TRLF compared with those who received RT (47.1% vs. 12.1%; P = 0.01). The RT cohort had improved OS compared with a frequency-matched NCDB chemotherapy-only cohort of supermassive ICC (37.6 vs. 8.9 months, P < 0.001). No major differences in mutational status or histopathology were noted between supermassive and nonsupermassive ICC tumors.Conclusions:Patients with supermassive ICC did not show a distinct mutational or histopathologic profile compared with those with nonsupermassive ICC and had promising outcomes with manageable toxicity when treated with ablative RT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy
Purpose:Ablative radiotherapy (RT) improves clinical outcomes in patients with unresectable intrahepatic cholangiocarcinoma (ICC). Applicability to “supermassive” ICC remains uncertain given smaller tumor diameters in previous studies. We hypothesize that supermassive ICCs are not mutationally or histopathologically different from nonsupermassive ICCs and so would respond favorably to ablative RT.Experimental Design:This is a retrospective study of patients with supermassive ICC treated at the University of Texas MD Anderson Cancer Center (MDACC) and the National Cancer Database (NCDB). Patients treated at MDACC with unresectable ICC, ≥10 cm in diameter, treated with ablative RT or chemotherapy alone were included. Among NCDB patients, patients treated with chemotherapy alone were included. We analyzed overall survival (OS), tumor-related liver failure (TRLF), and treatment toxicity. We further analyzed mutational status and histopathology in supermassive and nonsupermassive ICC tumors.Results:We identified 63 patients treated at MDACC. Patients treated with RT showed improved OS compared with patients treated with chemotherapy alone (median OS: 28.7 vs. 11.9 months; adjusted HR = 0.4; P = 0.02). Patients treated with chemotherapy alone had a higher rate of TRLF compared with those who received RT (47.1% vs. 12.1%; P = 0.01). The RT cohort had improved OS compared with a frequency-matched NCDB chemotherapy-only cohort of supermassive ICC (37.6 vs. 8.9 months, P < 0.001). No major differences in mutational status or histopathology were noted between supermassive and nonsupermassive ICC tumors.Conclusions:Patients with supermassive ICC did not show a distinct mutational or histopathologic profile compared with those with nonsupermassive ICC and had promising outcomes with manageable toxicity when treated with ablative RT.